NCT00002409已完成3 期
A Phase IIIB, Open-Label, Randomized Study of the Effect of an Education Intervention on Virological Outcomes, Adherence, Immunological Outcome, and Health Outcomes in HIV-Infected Subjects From Under-Represented Populations Treated With Triple Nucleoside Therapy (Combivir, Lamivudine 150 Mg/Zidovudine 300 Mg PO BID Plus Abacavir 300 Mg PO BID) for Twenty-Four Weeks
Glaxo Wellcome49 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2001年8月31日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 发起方
- 入组人数
- 200
- 试验地点
- 49
研究概览
简要总结
The purpose of this study is to see if an HIV-education course can help under-represented, HIV-infected patients. This study examines the areas of faithfulness to drug regimen, level of HIV in the blood, and health status.
详细描述
Following initial screening, eligible patients are treated with open-label Combivir plus abacavir for 24 weeks. Patients are randomized to undergo the education intervention, Tools for Health and Empowerment (T.H.E.) course plus counseling, or routine counseling only (control group). Measurements and evaluations for assessment of immunologic effects, adherence, and health outcomes are performed at entry (Day 1) and at Weeks 2, 5, 8, 12, 16, and 24.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have:
- •Documented and confirmed HIV infection.
- •Limited or no experience with antiretrovirals.
- •CD4+ lymphocyte cell count of 50 cells/mm3 or more 14 days prior to study drug administration.
- •HIV-1 plasma RNA above 40 copies/ml and less than 100,000 copies/ml within 14 days prior to study drug administration.
- •Ability to read, comprehend, and record information in fifth-grade English.
- •Ability to attend the 4 sessions of T.H.E. course on Weeks 1-4.
排除标准
- •Co-existing Condition:
- •Patients with the following symptoms or conditions are excluded:
- •Patients suffering from a serious medical condition such as diabetes, congestive heart failure, cardiomyopathy, or other cardiac dysfunction which would compromise the safety of the patient.
- •Malabsorption syndrome or other gastrointestinal dysfunction which may interfere with drug absorption or render the patient unable to take oral medication.
- •Acute or chronic active hepatitis.
- •Concurrent Treatment:
- •Treatment with foscarnet or other agents with required documented activity against HIV-1 in vitro.
- •Patients with the following prior conditions are excluded:
- •A clinical diagnosis of AIDS, according to the 1993 Centers for Disease Control (CDC) AIDS surveillance definition. (CD4 cell counts below 200 cells/mm3 will not be considered AIDS-defining.)
- •History of allergy to any study drug.
- •Prior Medication:
- •History of antiretroviral use. Patients with a history of sequential nucleoside monotherapy will be excluded, as will patients with a total antiretroviral history exceeding 6 months.
- •Required treatment with immunomodulating agents, such as systemic corticosteroids, interleukins, vaccines, or interferons, within 4 weeks prior to study entry, or an HIV immunotherapeutic vaccine within 3 months prior to entry. Asthmatic patients using inhaled corticosteroids are eligible for enrollment.
- •Prior Treatment:
- •Radiation therapy or cytotoxic chemotherapeutic agents received within 4 weeks prior to entry.
- •Risk Behavior:
- •Current alcohol or illicit drug use which may interfere with the ability to comply with dosing schedule and protocol evaluation and assessment.
研究者
研究点 (49)
Loading locations...
相似试验
撤回
1 期
HIV Educational Programs for Villagers of Funan County or Yingzhou District, Anhui Province, ChinaHIV InfectionsNCT00068991National Institute of Allergy and Infectious Diseases (NIAID)
进行中（未招募）
不适用
HIV Patients CohortPatients Affected by the HIVNCT02203006Assistance Publique - Hôpitaux de Paris1,613
已完成
4 期
Study of Reyataz in HIV-infected Patients With Lipodystrophy SyndromeHIV-Associated Lipodystrophy SyndromeNCT00135356Bristol-Myers Squibb219
已完成
2 期
Safety and Effectiveness of Giving an Anti-HIV Drug Combination of Adefovir Dipivoxil Plus Didanosine Plus Efavirenz Plus Lamivudine Once Daily to HIV-Infected PatientsHIV InfectionsNCT00002234Gilead Sciences25
已完成
4 期
Fosamprenavir Expanded AccessInfection, Human Immunodeficiency VirusNCT00240552ViiV Healthcare85